161 related articles for article (PubMed ID: 25636441)
1. Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus.
Rubin MR; Goldfine AB; McMahon DJ; Donovan DS; Cremers S; Dworakowski E; Schaefer EJ; Shoelson SE; Silverberg SJ
Endocrine; 2015 Nov; 50(2):504-7. PubMed ID: 25636441
[No Abstract] [Full Text] [Related]
2. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).
Goldfine AB; Buck JS; Desouza C; Fonseca V; Chen YD; Shoelson SE; Jablonski KA; Creager MA;
Diabetes Care; 2013 Dec; 36(12):4132-9. PubMed ID: 24130358
[TBL] [Abstract][Full Text] [Related]
3. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes.
Faghihimani E; Aminorroaya A; Rezvanian H; Adibi P; Ismail-Beigi F; Amini M
Acta Diabetol; 2013 Aug; 50(4):537-43. PubMed ID: 21938543
[TBL] [Abstract][Full Text] [Related]
4. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
Goldfine AB; Fonseca V; Jablonski KA; Chen YD; Tipton L; Staten MA; Shoelson SE;
Ann Intern Med; 2013 Jul; 159(1):1-12. PubMed ID: 23817699
[TBL] [Abstract][Full Text] [Related]
5. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes.
Goldfine AB; Silver R; Aldhahi W; Cai D; Tatro E; Lee J; Shoelson SE
Clin Transl Sci; 2008 May; 1(1):36-43. PubMed ID: 19337387
[TBL] [Abstract][Full Text] [Related]
6. Potential role of salicylates in type 2 diabetes.
Rumore MM; Kim KS
Ann Pharmacother; 2010; 44(7-8):1207-21. PubMed ID: 20516365
[TBL] [Abstract][Full Text] [Related]
7. Effect of diflunisal on platelet function and blood coagulation.
Sibinga CT
Br J Clin Pharmacol; 1977 Feb; 4 Suppl 1(Suppl 1):37S-38S. PubMed ID: 301745
[No Abstract] [Full Text] [Related]
8. Modeling diabetes disease progression and salsalate intervention in Goto-Kakizaki rats.
Cao Y; Dubois DC; Sun H; Almon RR; Jusko WJ
J Pharmacol Exp Ther; 2011 Dec; 339(3):896-904. PubMed ID: 21903749
[TBL] [Abstract][Full Text] [Related]
9. Salsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese hispanics.
Alderete TL; Sattler FR; Richey JM; Allayee H; Mittelman SD; Sheng X; Tucci J; Gyllenhammer LE; Grant EG; Goran MI
Obesity (Silver Spring); 2015 Mar; 23(3):543-51. PubMed ID: 25644856
[TBL] [Abstract][Full Text] [Related]
10. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.
Barzilay JI; Jablonski KA; Fonseca V; Shoelson SE; Goldfine AB; Strauch C; Monnier VM;
Diabetes Care; 2014 Apr; 37(4):1083-91. PubMed ID: 24255104
[TBL] [Abstract][Full Text] [Related]
11. Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults.
Hileman CO; Carman TL; Gripshover BM; O'Riordan M; Storer NJ; Harrill DE; White CA; McComsey GA
AIDS; 2010 Jul; 24(12):1958-61. PubMed ID: 20613460
[TBL] [Abstract][Full Text] [Related]
12. Comment on Goldfine et al. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes care 2013;36:4132-4139.
Pierce GL; Siefers K; Wegman-Points L
Diabetes Care; 2014 May; 37(5):e110-1. PubMed ID: 24757238
[No Abstract] [Full Text] [Related]
13. Acute systemic inhibition of inflammation augments endothelium-dependent dilation in women with a history of preeclamptic pregnancy.
Stanhewicz AE; Dillon GA; Serviente C; Alexander LM
Pregnancy Hypertens; 2022 Mar; 27():81-86. PubMed ID: 34973597
[TBL] [Abstract][Full Text] [Related]
14. Response to comment on Goldfine et al. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes care 2013;36:4132-4139.
Goldfine AB; Jablonski KA; Shoelson SE; Creager MA;
Diabetes Care; 2014 May; 37(5):e112. PubMed ID: 24757239
[No Abstract] [Full Text] [Related]
15. Salsalate has no effect on insulin secretion but decreases insulin clearance: a randomized, placebo-controlled trial in subjects without diabetes.
Penesova A; Koska J; Ortega E; Bunt JC; Bogardus C; de Courten B
Diabetes Obes Metab; 2015 Jun; 17(6):608-612. PubMed ID: 25683256
[TBL] [Abstract][Full Text] [Related]
16. Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease.
Leonhard WN; Song X; Kanhai AA; Iliuta IA; Bozovic A; Steinberg GR; Peters DJM; Pei Y
EBioMedicine; 2019 Sep; 47():436-445. PubMed ID: 31473186
[TBL] [Abstract][Full Text] [Related]
17. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Goldfine AB; Fonseca V; Jablonski KA; Pyle L; Staten MA; Shoelson SE;
Ann Intern Med; 2010 Mar; 152(6):346-57. PubMed ID: 20231565
[TBL] [Abstract][Full Text] [Related]
18. An overview of salsalate as a potential antidiabetic therapy.
Desouza CV
Drugs Today (Barc); 2010 Nov; 46(11):847-53. PubMed ID: 21225023
[TBL] [Abstract][Full Text] [Related]
19. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus.
Okazaki R; Miura M; Toriumi M; Taguchi M; Hirota Y; Fukumoto S; Fujita T; Tanaka K; Takeuchi A
Endocr J; 1999 Dec; 46(6):795-801. PubMed ID: 10724355
[TBL] [Abstract][Full Text] [Related]
20. Salsalate as an adjunctive treatment for psychopathology and cognition in patients with schizophrenia: a pilot study.
Luo Y; Liu F; Natarajan R; Shukair N; Copeland P; Fan X
Int Clin Psychopharmacol; 2018 Mar; 33(2):88-91. PubMed ID: 29084087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
